JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? (Q33341856)

25 July 2017

1 reference

title

JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? (English)

1 reference

25 July 2017

David P Steensma

2

0 references

author name string

Maria E Nelson

series ordinal

1

1 reference

25 July 2017

publication date

1 February 2006

1 reference

25 July 2017

1 reference

25 July 2017

volume

47

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

177-194

1 reference

The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Imatinib as a paradigm of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Clonal origin of chronic myelocytic leukemia in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Polycythemia vera: stem-cell and probable clonal origin of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Chronic myeloid disorders: Classification and treatment overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The chronic myeloproliferative disorders: clonality and clinical heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Chronic myelogenous leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Structural organization of the bcr gene and its role in the Ph' translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Mutations in the VHL gene in sporadic apparently congenital polycythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Cytogenetic and molecular genetic aspects of essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Molecular genetics and cytogenetics of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The JAK/STAT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

21 January 2018

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Cytokine receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Turning cells red: signal transduction mediated by erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

STAT proteins: From normal control of cellular events to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of stat signals during red blood cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Activated Stat related transcription factors in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Constitutive activation of STAT transcription factors in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Increased expression of the INK4a/ARF locus in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Series introduction. JAK-STAT signaling in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

On the molecular origins of the chronic myeloproliferative disorders: it all makes sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Diagnosing polycythemia vera: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Polycythemia vera: myths, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Essential thrombocythaemia: challenges and evidence-based management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500301348

10.1080/10428190500301348

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference